Selective impairment of TLR-mediated innate immunity in human newborns: Neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848

Journal of Immunology

Volumn 173, Issue 7, 2004, Pages 4627-4634

  Levy, Ofer ^a,b,c   Zarember, Kol A ^d   Roy, Rene M ^a,b   Cywes, Colette ^a,c   Godowski, Paul J ^d   Wessels, Michael R ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; LIPOPEPTIDE; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; RESIQUIMOD; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; INFECTION RISK; INFECTION SENSITIVITY; MALE; MONOCYTE; NEWBORN; NEWBORN INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL CORD BLOOD;

EID: 4644307506     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.7.4627     Document Type: Article

References (32)

1. Klein, J., and J. Remington. 2001. Current concepts of infections of the fetus and newborn infant. In Infectious Diseases of the Fetus and Newborn Infant. J. Remington and J. Klein, eds. Saunders, Philadelphia, p. 1.
2. Zinkernagel, R. M. 2001. Maternal antibodies, childhood infections, and autoimmune diseases. N. Engl. J. Med. 345:1331.
3. Lewis, D. B., and C. B. Wilson. 2001. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Infectious Diseases of the Fetus and Newborn Infant. J. Remington and J. Klein, eds. Saunders, Philadelphia, p. 25.
4. Hoffman, J., F. Kafatos, C. Janeway, and R. Ezekowitz. 1999. Phylogenetic perspectives in innate immunity. Science 284:1313.
5. Landmann, R., B. Muller, and W. Zimmerli. 2000. CD14, new aspects of ligand and signal diversity. Microbes Infect. 2:295.
6. Stanley, M. A. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27:571.
7. Hemmi, H., T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi, H. Tomizawa, K. Takeda, and S. Akira. 2002. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3:196.
8. Jurk, M., F. Heil, J. Vollmer, C. Schetter, A. M. Krieg, H. Wagner, G. Lipford, and S. Bauer. 2002. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat. Immunol. 3:499.
9. Harandi, A. M., J. Sanchez, K. Eriksson, and J. Holmgren. 2003. Recent developments in mucosal immunomodulatory adjuvants. Curr. Opin. Invest. Drugs 4:156.
10. Jones, T. 2003. Resiquimod 3M. Curr. Opin. Invest. Drugs 4:214.
11. Ulevitch, R. J., and P. S. Tobias. 1999. Recognition of Gram-negative bacteria and endotoxin by the innate immune system. Curr. Opin. Immunol. 11:19.
12. Vreugdenhil, A. C., C. H. Rousseau, T. Hartung, J. W. Greve, C. van'tVeer, and W. A. Buurman. 2003. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J. Immunol. 170:1399.
13. Kitchens, R. L., P. A. Thompson, S. Viriyakosol, G. E. O'Keefe, and R. S. Munford. 2001. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J. Clin. Invest. 108:485.
14. Akira, S. 2003. Toll-like receptor signaling. J. Biol. Chem. 278:38105.
15. Akira, S. 2003. Mammalian Toll-like receptors. Curr. Opin. Immunol. 15:5.
16. Cohen, L., A. Haziot, D. R. Shen, X. Y. Lin, C. Sia, R. Harper, J. Silver, and S. M. Goyert, 1995. CD14-independent responses to LPS require a serum factor that is absent from neonates. J. Immunol. 155:5337.
17. Bessler, H., L. Komlos, I. Punsky, J. A. Ntambi, M. Bergman, R. Straussberg, and L. Sirota. 2001. CD14 receptor expression and lipopolysaccharide-induced cytokine production in preterm and term neonates. Biol. Neonate 80:186.
18. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165:618.
19. Yan, S. R., G. Qing, D. M. Byers, A. W. Stadnyk, W. Al-Hertani, and R. Bortolussi. 2004. Role of MyD88 in diminished tumor necrosis factor α production by newborn mononuclear cells in response to lipopolysaccharide. Infect. Immun. 72:1223.
20. Biesert, L., W. Scheuer, and W. G. Bessler. 1987. Interaction of mitogenic bacterial lipoprotein and a synthetic analogue with mouse lymphocytes: isolation and characterization of binding proteins. Eur. J. Biochem. 162:651.
21. Muhlradt, P. F., M. Kiess, H. Meyer, R. Sussmuth, and G. Jung. 1997. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J. Exp. Med. 185:1951.
22. Levy, O., R. Jean-Jacques, C. Cywes, R. Sisson, K. A. Zarember, P. J. Godowski, J. Christianson, H. K. Guttormsen, M. C. Carroll, A. Nicholson-Weller, et al. 2003. Critical role of the complement system in group B streptococcus-induced tumor necrosis factor α release. Infect. Immun. 71:6344.
23. Zarember, K. A., and P. J. Godowski. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. [Published erratum appears in 2002 J. Immunol. 169:1136]. J. Immunol. 168:554.
24. Zarember, K. A., and P. J. Godowski. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. [Published erratum appears in 2002 J. Immunol. 169:1136]. J. Immunol. 168:554.
25. Brown, M. A., P. Y. Rad, and M. J. Halonen. 2003. Method of birth alters interferon-γ and interleukin-12 production by cord blood mononuclear cells. Pediatr. Allergy Immunol. 14:106.
26. Uehara, A., S. Sugawara, R. Tamai, and H. Takada. 2001. Contrasting responses of human gingival and colonic epithelial cells to lipopolysaccharides, lipoteichoic acids and peptidoglycans in the presence of soluble CD14. Med. Microbiol. Immunol. 189:185.
27. Holmlund, U., A. Hoglind, A. K. Larsson, C. Nilsson, and E. Sverremark Ekstrom. 2003. CD14 and development of atopic disease at 2 years of age in children with atopic or non-atopic mothers. Clin. Exp. Allergy 33:455.
28. Bracci, R., and G. Buonocore. 2003. Chorioamnionitis: a risk factor for fetal and neonatal morbidity. Biol. Neonate 83:85.
29. Massari, P., P. Henneke, Y. Ho, E. Latz, D. T. Golenbock, and L. M. Wetzler. 2002. Cutting edge: immune stimulation by Neisserial porins is Toll-like receptor 2 and MyD88 dependent. J. Immunol. 168:1533.
30. Rharbaoui, F., B. Drabner, S. Borsutzky, U. Winckler, M. More, B. Ensoli, P. F. Muhlradt, and C. A. Guzman. 2002. The mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant. Eur. J. Immunol. 32:2857.
31. Sieling, P. A., W. Chung, B. T. Duong, P. S. Godowski, and R. L. Modlin. 2003. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170:194.
32. Bernstein, D. I., R. L. Miller, and C. J. Harrison. 1993. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J. Infect. Dis. 167:731.